AcelRx Q3 net loss $1.4M; Niyad gets FDA IDE approval, registrational study to start Q4

TALPHERA, INC.

2023-Q3 EPS reported -$1.08 revenue$370,000

Net loss from continuing ops $1.4M ($0.08/sh); revenue $0.1M from DSUVIA royalty.
Cash $13.4M at Sep 30; Oxford senior debt fully repaid in Q2 2023.
FDA IDE approval for Niyad (regional anticoagulant for dialysis); NEPHRO study to start Q4, data mid-2024.
July private placement raised $10M, with potential $16.3M additional upon milestone warrants.
Combined R&D and SG&A expenses $3.4M, down from $4.5M YoY; headcount reduction offset by Niyad costs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TALPHERA, INC. reported the three months ended September 30, 2023 results: revenue $0.1 million, net income $1.4 million, EPS $0.08 per basic and diluted share.

Period: the three months ended September 30, 2023
Revenue: $0.1 million
Net income: $1.4 million
EPS: $0.08 per basic and diluted share
Result: reported results

Exact text from the filing

● The cash and cash equivalents balance was $13.4 million as of September 30, 2023. The senior debt with Oxford was fully repaid in the second quarter of 2023. ● Revenues of $0.1 million for the third quarter primarily represent the royalty revenue earned on the sales of DSUVIA by Alora, principally driven by sales to the Department of Defense. Revenues in the

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-030955

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.